2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCohort StudiesConnecticutCOVID-19COVID-19 SerotherapyFemaleHospital MortalityHumansImmunization, PassiveInpatientsLength of StayMaleMiddle AgedPropensity ScoreRandomized Controlled Trials as TopicSARS-CoV-2Treatment OutcomeConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseEffect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial
Sanft T, Harrigan M, Cartmel B, Ferrucci LM, Li FY, McGowan C, Zupa M, Nguyen TH, Ligibel J, Neuhouser ML, Hershman DL, Basen-Engquist K, Jones B, Knobf T, Chagpar A, Silber A, Irwin ML. Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial. Contemporary Clinical Trials 2021, 109: 106508. PMID: 34274495, PMCID: PMC10424280, DOI: 10.1016/j.cct.2021.106508.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsDiet, HealthyExerciseFemaleHumansLife StyleQuality of LifeRandomized Controlled Trials as TopicConceptsChemotherapy completion rateTreatment-related side effectsPhysical activity guidelinesBreast cancerActivity guidelinesCancer survivorsSide effectsWorld Cancer Research FundUsual care control groupCompletion ratesEndocrine therapy adherenceCare control groupHealthy lifestyle interventionRandomized clinical trialsPatient reported outcomesPhysical activity interventionsBreast cancer treatmentAmerican Cancer SocietyBreast cancer prognosisCancer Research FundElectronic medical recordsOncology nutritionTreating oncologistSecondary endpointsChemotherapy session
2020
Revascularization Options for Females With Multivessel Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials
Gul B, Shah T, Head SJ, Chieffo A, Hu X, Li F, Brackett A, Gesick C, Bisarya PK, Lansky A. Revascularization Options for Females With Multivessel Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials. JACC Cardiovascular Interventions 2020, 13: 1009-1010. PMID: 32113933, DOI: 10.1016/j.jcin.2019.12.036.Peer-Reviewed Original ResearchMeSH KeywordsCoronary Artery BypassCoronary Artery DiseaseFemaleHumansPercutaneous Coronary InterventionRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSex FactorsTreatment Outcome